The 10 most recent market catalysts affecting $ENLV, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Bearish
Impact 85
Enlivex shares are trading lower after the company announced the termination of its agreement to sell 66,666,667 shares to the Rain Foundation in exchange for RAIN tokens.
The termination of a significant share sale agreement, especially one involving a large number of shares (66,666,667), is a major negative catalyst for Enlivex. This deal was likel…
Sep 22, 2026
Corporate Catalyst
Neutral
Impact 85
Enlivex Announces Termination Of 66,666,667-Share Private Placement With Rain Foundation For RAIN Tokens
The termination of a private placement of 66,666,667 shares is a substantial event for a company like Enlivex, representing a significant chunk of potential funding. This move coul…
Aug 6, 2026
Corporate Catalyst
Neutral
Impact 65
Enlivex Announced Filing Of Prospectus For Resale Of Up To 10M Ordinary Shares By Selling Shareholder
The filing of a prospectus for the resale of up to 10 million ordinary shares by a selling shareholder for Enlivex (ENLV) is a moderate corporate catalyst. This event increases the…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 65
HC Wainwright & Co. Maintains Buy on Enlivex, Raises Price Target to $80
HC Wainwright & Co. analyst Raghuram Selvaraju maintained a 'Buy' rating on Enlivex (ENLV) and dramatically raised the price target from $20 to $80. This significant increase in th…
Jul 30, 2026
Corporate Catalyst
Neutral
Impact 65
Enlivex Announces Trading Volume On Rain Protocol Reaches $860M
Enlivex, identifying as a 'quality longevity company powered by a prediction markets treasury,' is reporting on the trading metrics of the Rain protocol. The significant increase i…
Jul 28, 2026
Corporate Catalyst
Bearish
Impact 85
Enlivex shares are trading lower after the company announced a $400 million private placement.
The $400 million private placement for Enlivex Therapeutics (ENLV) is a significant dilutive event for existing shareholders, leading to a sharp decline in share price. While such …
Jul 28, 2026
Corporate Catalyst
Neutral
Impact 85
Enlivex Announces $400M Private Placement With A Single Institutional Investor Priced At $5.00 Per Share
Enlivex Therapeutics announced a $400 million private placement, a substantial capital infusion for a company of its size. The most notable aspect is the acceptance of RAIN tokens …
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 65
Enlivex shares are trading higher after the company announced its RAIN token holdings.
The headline indicates a direct positive impact on Enlivex's stock due to its RAIN token holdings. This suggests that investors are viewing the company's digital asset strategy fav…
Jul 20, 2026
Corporate Catalyst
Neutral
Impact 75
Enlivex Updates RAIN Token Holings; Net Asset Value Per Ordinary Share $66.16; Company Held 79,550,593,122 RAIN Tokens Valued At ~$1.1B
This headline is a significant corporate catalyst for Enlivex (ENLV) as it provides a clear valuation of its substantial RAIN token holdings, leading to a high Net Asset Value per …
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 75
FDA Grants Enlivex Regenerative Medicine Advanced Therapy Designation To Allocetra
The FDA's Regenerative Medicine Advanced Therapy (RMAT) designation is a powerful regulatory tool designed to expedite the development and review of regenerative medicine therapies…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.